Skip to content

Use of botulinum toxin a to manage upper limb spasticity in children with cerebral palsy

Upper limb resistance training and the use of botulinum toxin A (BTX-A) to improve upper limb function in children with cerebral palsy: An investigation of functional benefit, and peripheral and central nervous system changes.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12607000486426
Enrollment
25
Registered
2007-09-21
Start date
2005-07-04
Completion date
2005-10-03
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Objective: To investigate the impact on of conventional therapy and resistance therapy augmented with botulinum toxin A (BoNTA) in children with hemiplegic cerebral palsy (CP) on upper limb (UL) function and quality of movement. Assessment of movement quality was considered important, because early brain injuries are more susceptible to 'maladaptative' plasticity, which might result in abnormal movement behaviours. Study Design: Single blind, randomised control trial (RCT) using matched pairs. Methods: A control group continued with their usual community based ‘conventional’ therapy. The treatment group received either 1. BoNTA injections to the upper limb with conventional therapy or; 2. BoNTA injections to the upper limb with conventional therapy plus upper limb resistance training at the peak effect of the BoNTA. Twenty-five participants aged between 8 and 16 years were enrolled. Assessments for this group included the Melbourne Assessment of Unilateral Upper Limb Function (MUUL); goal attainment using goal attainment scales (GAS) and kinematic analysis of reaching with the quantification of normalised jerk (NJ) reflecting movement fluency, and directness index (DI) reflecting movement efficiency. CNS changes were measured using Transcranial Magnetic Stimulation to map corticospinal pathways. Results: GAS improved significantly in recipients who received resistance training augmented with BoNTA relative to controls at 1, 3 and 6 months (mean 58.1, SD 11.1, p<0.05). Therapy augmented with BoNTA resulted in improvements in movement fluency and efficiency and neuroplastic changes in some, but not all the children studied. The children who had preserved contralateral corticospinal pathways displayed less maladaptive movement behaviour with lower variability of NJ and DI, and higher MUUL score. Conclusion: Augmenting physical therapies with BoNTA improves function, movement fluency and induces CNS changes in children with hemiplegic spastic CP. More significant gains in UL function were achieved in a shorter time when muscle resistance training was combined with BoNTA and maintained after the effect of the BoNTA had worn off.

Interventions

Intramuscular injection of botulinum toxin A (BoNTA) to selected upper limb muscles at 0.5-2u/kg/body weight followed by resistance training at the peak effect of the BoNTA (6 weeks post injection). Resistance training consists of selected weighted exercises at 80% 0f 1 repetition max, repeated 5 days a week for 6 weeks with weight progressed weekly.

Sponsors

Princess Margaret Hospital
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
8 Years to 16 Years
Healthy volunteers
No

Inclusion criteria

Age hemiplegia due to cerebral palsy spasticity

Exclusion criteria

unable to complete all testing

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026